SCHEMBL4156450

SCHEMBL4156450

O=C(Nc1cccnc1)c1ccnc2[nH]c(-c3ccc(F)cc3)nc12

nearest known ligand 0.74

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 5/20 0.74
CYP11B2 P19099 3/20 0.54
CYP11B1 P15538 2/20 0.54
KDM4E B2RXH2 2/20 0.50
ALDH1A1 P00352 2/20 0.50
TDP1 Q9NUW8 1/20 0.50
LMNA P02545 1/20 0.50
HTT P42858 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
CLK2 P49760 1/20 0.49
LRRK2 Q5S007 3/20 0.48
MCL1 Q07820 1/20 0.48
EGLN1 Q9GZT9 1/20 0.47
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
SGMS2 Q8NHU3 1/20 0.45
HPGD P15428 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4152144 0.90 GSK3B (0.60) GSK3BKDM4EALDH1A1LMNAMEN1
SCHEMBL4152791 0.88 GSK3B (0.73) GSK3BALDH1A1L3MBTL1
SCHEMBL4152806 0.88 GSK3B (0.57) GSK3BKDM4EALDH1A1LMNAHTT
SCHEMBL4152265 0.86 GSK3B (0.56) GSK3BCYP11B2KDM4EALDH1A1LMNA
SCHEMBL4152183 0.86 GSK3B (0.56) GSK3B
SCHEMBL4161516 0.84 GSK3B (0.54) GSK3BKDM4EALDH1A1MEN1KMT2A
SCHEMBL4169328 0.84 GSK3B (0.55) GSK3BALDH1A1LMNAHTTCLK2
SCHEMBL4161438 0.83 GSK3B (0.56) GSK3BLMNAL3MBTL1MEN1KMT2A
SCHEMBL4153017 0.83 GSK3B (0.56) GSK3BKDM4EALDH1A1LMNAL3MBTL1
SCHEMBL4154104 0.83 GSK3B (0.56) GSK3BTDP1LMNAL3MBTL1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same YUYU PHARMA, INC. (KR) 2009-07-02 US claimed
EP-1984370-A1 IMIDAZOPYRIDINE DERIVATIVES INHIBITING PROTEIN KINASE ACTIVITY, METHOD FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING SAME Crystalgenomics, Inc. (KR) 2008-10-29 EP claimed
WO-2007083978-A1 IMIDAZOPYRIDINE DERIVATIVES INHIBITING PROTEIN KINASE ACTIVITY, METHOD FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING SAME CRYSTALGENOMICS, INC. (KR) 2007-07-26 WO claimed
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same YUYU PHARMA, INC. (KR) 2009-07-02 US disclosed
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same YUYU PHARMA, INC. (KR) 2009-07-02 US disclosed
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same YUYU PHARMA, INC. (KR) 2009-07-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same GSK3B, GSK3A, MAP3K3 GSK3B 1/4885CYP11B2 1148/4885CYP11B1 866/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.